Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02674061
Title Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer



Age Groups: adult
Covered Countries

No variant requirements are available.